Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Notes Payables (2016 - 2019)

Ironwood Pharmaceuticals' Notes Payables history spans 5 years, with the latest figure at $48.8 million for Q2 2019.

  • On a quarterly basis, Notes Payables rose 96.28% to $48.8 million in Q2 2019 year-over-year; TTM through Jun 2019 was $48.8 million, a 96.28% increase, with the full-year FY2018 number at $47.6 million, changed N/A from a year prior.
  • Notes Payables hit $48.8 million in Q2 2019 for Ironwood Pharmaceuticals, up from $46.0 million in the prior quarter.
  • Over the last five years, Notes Payables for IRWD hit a ceiling of $48.8 million in Q2 2019 and a floor of $8.4 million in Q3 2016.
  • Historically, Notes Payables has averaged $28.2 million across 4 years, with a median of $25.0 million in 2015.
  • Biggest five-year swings in Notes Payables: crashed 58.23% in 2016 and later skyrocketed 284.35% in 2019.
  • Tracing IRWD's Notes Payables over 4 years: stood at $25.0 million in 2015, then plummeted by 66.33% to $8.4 million in 2016, then skyrocketed by 465.78% to $47.6 million in 2018, then increased by 2.61% to $48.8 million in 2019.
  • Business Quant data shows Notes Payables for IRWD at $48.8 million in Q2 2019, $46.0 million in Q1 2019, and $47.6 million in Q4 2018.